Summit Therapeutics (SMMT) is back in focus after expanding its ivonescimab program with a new global Phase II/III bladder cancer trial, updated survival data in lung cancer, and a kidney cancer collaboration with Arcus Biosciences.
See our latest analysis for Summit Therapeutics.
The latest ivonescimab updates come after a period where Summit Therapeutics’ share price has been volatile. The 1-year total shareholder return declined 51.75%, and the 3-year total shareholder return was very large, while the year-to-date share price return is down 21.46% despite a 1-day gain of 5.48%.
If you are tracking how oncology developments can move early-stage stocks, it may also be worth scanning a focused list of healthcare AI opportunities via the 41 healthcare AI stocks.
Bulls point to Summit Therapeutics’ multi tumor ivonescimab data and expanding trials, while bears focus on heavy losses and fresh equity issuance. Which side does the current valuation lean toward as the market prices in this latest move?
Most Popular Narrative: 51.5% Undervalued
Summit Therapeutics closed at $13.76 while the most widely followed narrative puts fair value at $28.36. That gap rests heavily on ambitious ivonescimab assumptions.
The breadth of ivonescimab clinical activity across at least 15 Phase III trials and more than 4,000 treated patients positions Summit to participate in the long term shift toward combination immuno oncology and anti angiogenic regimens in multiple tumor types, which is most relevant for potential future revenue growth.
Want to see what sits behind that crowded trial map? The narrative leans on an aggressive revenue build, expectations of richer margins and a premium future earnings multiple.
Result: Fair Value of $28.36 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Summit Therapeutics still faces key risks, including heavy R&D spending with no current revenue and the possibility that major ivonescimab trials fail to meet regulatory expectations.
Find out about the key risks to this Summit Therapeutics narrative.
Next Steps
With mixed signals on risks and rewards around Summit Therapeutics, this is a moment to move quickly and check the underlying detail for yourself through the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Summit Therapeutics?
If Summit Therapeutics has your attention, do not stop there. Use the Simply Wall St screener to quickly spot other stocks that might suit your approach.
- Target resilient potential by scanning 82 resilient stocks with low risk scores that aim to limit downside while still keeping you exposed to meaningful upside.
- Hunt for strong fundamentals through the solid balance sheet and fundamentals stocks screener (49 results) and focus on companies with healthier financial footing.
- Unearth early opportunities with the screener containing 18 high quality undiscovered gems before they appear on everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com